TY - JOUR
T1 - A new immunomodulatory therapy for severe sepsis
T2 - Ulinastatin plus thymosin α 1
AU - Yumin, Li
AU - Hao, Chen
AU - Xun, Li
AU - Wence, Zhou
AU - Minyan, He
AU - Chiriva-Internati, M.
AU - Wachtel, M. S.
AU - Frezza, E. E.
PY - 2009/1
Y1 - 2009/1
N2 - Objectives: To study the effect of immunomodulatory therapy with ulinastatin plus thymosin α1 on septic patients. Method: A total of 56 sepsis patients were randomized into a treatment group, receiving immunomodulatory therapy, and a placebo group, a placebo. Acute Physiology and Chronic Health Evaluation II scores, clinical data, lymphocyte subsets, immunological indexes, and coagulation parameters were determined before admission and on the 3rd, 8th, and 28th day after admission to the Intensive Care Unit. Results: The treatment group experienced a 78% cumulative survival, the placebo group experienced a 60% cumulative survival; the survival difference was mirrored by Acute Physiology and Chronic Health Evaluation II scores and more quickly improved leukocyte counts, lymphocyte counts, coagulation parameters, and cytokine levels in the treatment. Conclusions: Combined immunomodulatory therapy with ulinastatin plus thymosin α1 appears to yield improved survival for patients with sepsis; this finding should be verified in larger clinical trials.
AB - Objectives: To study the effect of immunomodulatory therapy with ulinastatin plus thymosin α1 on septic patients. Method: A total of 56 sepsis patients were randomized into a treatment group, receiving immunomodulatory therapy, and a placebo group, a placebo. Acute Physiology and Chronic Health Evaluation II scores, clinical data, lymphocyte subsets, immunological indexes, and coagulation parameters were determined before admission and on the 3rd, 8th, and 28th day after admission to the Intensive Care Unit. Results: The treatment group experienced a 78% cumulative survival, the placebo group experienced a 60% cumulative survival; the survival difference was mirrored by Acute Physiology and Chronic Health Evaluation II scores and more quickly improved leukocyte counts, lymphocyte counts, coagulation parameters, and cytokine levels in the treatment. Conclusions: Combined immunomodulatory therapy with ulinastatin plus thymosin α1 appears to yield improved survival for patients with sepsis; this finding should be verified in larger clinical trials.
KW - APACHE II
KW - Clinical trial
KW - Immunomodulatory therapy
KW - Sepsis
KW - Thymosin α1
KW - Ulinastatin
UR - http://www.scopus.com/inward/record.url?scp=58349089304&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58349089304&partnerID=8YFLogxK
U2 - 10.1177/0885066608326970
DO - 10.1177/0885066608326970
M3 - Article
C2 - 19033321
AN - SCOPUS:58349089304
SN - 0885-0666
VL - 24
SP - 47
EP - 53
JO - Journal of Intensive Care Medicine
JF - Journal of Intensive Care Medicine
IS - 1
ER -